For millions of Americans, the success of GLP-1 weight loss drugs is bringing an unexpected set of aesthetic challenges. Although medications like Ozempic and Wegovy are delivering on their primary promise of rapid weight reduction, they are simultaneously creating a burgeoning market for “corrective” beauty—sending a new wave of customers to retailers like Ulta Beauty to treat the side effects of their success.
Kecia Steelman, President and CEO of Ulta Beauty, has observed a distinct shift in consumer behavior as GLP-1 users seek to mitigate the physical tolls of fast weight loss. In a recent interview with Yahoo Finance’s Opening Bid, Steelman noted that the demand for products addressing hair loss and skin elasticity is on the rise. “Hair loss with GLP-1s is real, and products that can help with that,” Steelman said, adding that rapid weight loss necessitates a focus on moisture and skin elasticity to maintain a healthy appearance.
The Pursuit of ‘Gaze Longevity’
This trend has created a surprising demographic crossover. Steelman pointed out that GLP-1 users are now seeking the same types of products as those managing aging skin. Both groups are essentially chasing “the longevity of the look,” focusing on maintenance and restoration as their physical compositions change.
The phenomenon extends beyond the aisles of beauty retailers. The “Ozempic face”—a sunken appearance caused by rapid fat loss in the cheeks and temples—has driven demand for facial fillers, a trend noted by the CEO of Swiss pharmaceutical giant Galderma. Even the fashion industry is feeling the ripple effects; Wall Street tailors reported in January that clients are returning entire wardrobes to be taken in to fit their new frames.
A Strategic Pivot Toward Wellness
For Ulta Beauty, these shifts align with a broader organizational transformation. Since taking the helm in January 2025, Steelman has implemented the “Ulta Beauty Unleashed” plan, a strategy designed to reinvigorate the brand and accelerate growth. The company’s focus on skincare, wellness, and hair care—categories that now account for 43% of total sales—positions it to capture the specific needs of the GLP-1 population.

The financial results of this pivot are evident. Ulta reported 2025 annual sales of approximately $12.39 billion, an 11.8% increase over the previous year. This growth has been supported by an expanded digital presence, including a new online marketplace and the acquisition of U.K. Retailer SpaceNK. With the company’s stock price rising about 50% over the past year, the intersection of pharmaceutical trends and beauty retail appears to be a significant growth engine.
While the pharmaceutical side of the equation focuses on weight, the retail side is now focusing on the aftermath. For Ulta, the goal is to provide the tools to ensure that the physical transformation of weight loss doesn’t come at the cost of aesthetic confidence.
How common is hair loss among GLP-1 users?
While the exact prevalence across all users is not specified, data from Wegovy clinical trials indicated that hair loss was reported as a side effect in 3% of participants.
Which product categories are seeing the most growth?
Demand is specifically increasing for anti-hairfall treatments and products designed to improve skin elasticity and moisture, as rapid weight loss can abandon skin looking depleted.
What does this mean for the broader beauty industry?
The trend suggests a shift toward “functional beauty,” where products are used not just for enhancement but to counteract specific medical side effects. This could lead to deeper integrations between wellness, dermatology, and traditional cosmetics.
Is this trend sustainable for retailers?
Given that an estimated 10% of the U.S. Population is using these drugs, the market for corrective care is likely to remain robust as long as GLP-1 prescriptions continue to rise and users seek to maintain their appearance during rapid weight loss.
As weight-loss medications continue to reshape the American silhouette, will the beauty industry move toward creating specialized “GLP-1 recovery” product lines?






